Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 6, 2008, Pages 609-613

  Danger, Richard ^a,b   Giral, Magali ^b   Soulillou, Jean Paul ^a,b   Brouard, Sophie ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Calcineurin inhibitor withdrawal; Immunosuppression; Kidney transplant; Predictor; Rejection

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GRANULYSIN; GRANZYME B; HLA ANTIBODY; INDOLEAMINE 2,3 DIOXYGENASE; KIDNEY INJURY MOLECULE 1; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TACROLIMUS; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRIBBLES 1 PROTEIN; UNCLASSIFIED DRUG; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG SAFETY; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAPLOTYPE; HLA MATCHING; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; PATIENT SELECTION; REVIEW; RISK FACTOR; ALLOTRANSPLANTATION; ANIMAL; BIOPSY; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GRAFT REJECTION; KIDNEY DISEASE; METABOLISM; PATHOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BIOPSY; CALCINEURIN; DRUG ADMINISTRATION SCHEDULE; GENETIC PREDISPOSITION TO DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 60849114992     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283193bd8     Document Type: Review

References (43)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
2. Barbari AG, Stephan AG, Masri MA. Calcineurin inhibitor-free protocols: risks and benefits. Saudi J Kidney Dis Transpl 2007; 18:1-23.
3. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7:560-570.
4. Anjum S, Andany MA, McClean JC, et al. Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am J Transplant 2002; 2:179-185.
5. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16:2234-2240.
6. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16:2509-2516.
7. Hazzan M, Buob D, Labalette M, et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006; 82:657-662.
8. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008; 8:1529-1536.
9. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-760.
10. Thaunat O, Legendre C, Morelon E, et al. To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation 2007; 84:671-676.
11. Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation 2006; 81:202-206.
12. Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008; 21:152-155.
13. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006; 70:1694-1705.
14. Ahmed K, Ahmad N, Khan MS, et al. Influence of number of retransplants on renal graft outcome. Transplant Proc 2008; 40:1349-1352.
15. Douverny JB, Baptista-Silva JC, Pestana JOM, Sesso R. Importance of renal mass on graft function outcome after 12 months of living donor kidney transplantation. Nephrol Dial Transplant 2007; 22:3646-3651.
16. Chang SH, Coates PTH, McDonald SP. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation 2007; 84:981-987.
17. Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006; 354:343-352.
18. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6:747-752.
19. de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12:1538-1546.
20. Øien CM, Reisaeter AV, Leivestad T, et al. Living donor kidney transplantation: the effects of donor age and gender on short- and long-term outcomes. Transplantation 2007; 83:600-606.
21. Mikhalski D, Wissing KM, Ghisdal L, et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008; 85 (7 Suppl):S3-S9.
22. Pallardo LM, Oppenheimer F, Guirado L, et al. Calcineurin inhibitor reduction based on maintenance immunosuppression with mycophenolate mofetil in renal transplant patients: POP study. Transplant Proc 2007; 39:2187-2189.
23. Opelz G, Döhler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85:661-666.
24. Giral-Classe M, Hourmant M, Cantarovich D, et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998; 54:972-978.
25. MessaP, Brezzi B, Cresseri D, et al. Immediate graft function positively affects long-term outcome of renal allografts from older but not from younger donors. Transplant Proc 2006; 38:3377-3381.
26. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7:864-871.
27. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16:2804-2812.
28. Abramowicz D, HadayaK, Hazzan M, et al. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008. [Epub ahead of print]
29. Brouard S, Ashton-Chess J, Soulillou J. Surrogate markers for the prediction of long-term outcome in transplantation: Nantes Actualité Transplantation (NAT) 2007 meeting report. Hum Immunol 2008; 69:2-8.
30. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008; 86:192-199.
31. Braudeau C, Ashton-Chess J, Giral M, et al. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 2008; 86:130-136.
32. Brandacher G, Cakar F, Winkler C, et al. Noninvasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007; 71:60-67.
33. Ashton-Chess J, Giral M, Mengel M, et al. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol 2008; 19:1116-1127.
34. van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 2007; 84:1625-1630.
35. Vaidya S, Partlow D, Barnes T, Gugliuzza K. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006; 82:1606-1609.
36. Matz M, Beyer J, Wunsch D, et al. Early posttransplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 2006; 69:1683-1690.
37. Braudeau C, Racape M, Giral M, et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transplant Int 2007; 20:845-855.
38. + lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17:294-304.
39. Israni AK, Li N, Sidhwani S, et al. Association of hypertension genotypes and decline in renal function after kidney transplantation. Transplantation 2007; 84:1240-1247.
40. Rérolle J, Munteanu E, Drouet M, et al. PAI-1 donor polymorphism influences long-term kidney graft survival. Nephrol Dial Transplant 2008; 23:3325-3332.
41. Kruger B, Schröppel B, Ashkan R, et al. A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002; 13:2585-2589.
42. Kang SW, Park SJ, Kim YW, et al. Association of MCP-1 and CCR2 polymorphisms with the risk of late acute rejection after renal transplantation in Korean patients. Int J Immunogenet 2008; 35:25-31.
43. Nankivell BJ, Borrows RJ, Fung CLS, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78:557-565.